BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BC Week In Review | Oct 13, 2014
Company News

Bristol-Myers, Novartis deal

Bristol-Myers and Novartis partnered to run two Phase I/II trials to evaluate combinations of BMS's Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC). The Novartis therapies are Zykadia ceritinib, INC280...
BC Extra | Oct 7, 2014
Company News

BMS, Novartis to test combinations for NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) and Novartis AG (NYSE:NVS; SIX:NOVN) have partnered to run two Phase I/II trials to evaluate combinations of BMS' Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC)....
Items per page:
1 - 3 of 3